Related Experiment Video
Updated: May 30, 2026

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth
Published on: December 22, 2020
Sp1king out cancer (....and fibrosis?)
1Department of Dentistry, University of Western Ontario, London, ON, Canada, NGA 5C1, Andrew.leask@schulich.uwo.ca.
Abstract:
It is becoming increasingly apparent that many of the basic mechanisms underlying cancers also underlie fibrotic diseases. For example, the Sp1 family of transcription factors plays an essential role in controlling the gene expression of proteins that promote both oncogenesis and fibrogenesis. The drug mithramycin, which prevents Sp1 binding to DNA, has been in use clinically for some cancers, but has side-effects. However, other drugs exist that affect Sp1 activity through promoting Sp1 protein degradation. Evidence has emerged that low levels of mithramycin can be combined with these drugs to result in potent antitumorigenic effects without resulting in obvious toxicity (Gao et al. Cancer Res 2011 Jun 20; Jia et al. Cancer Res 70:1111-1119, 2010). Given that Sp1 proteins also promote expression of profibrotic genes such as collagen type I and CCN2, it is possible that this combinatorial approach may be taken in the future to block not only cancer but also fibrosis.
Insights
The Sp1 transcription factor drives both cancer and fibrosis. Combining low-dose mithramycin with drugs that degrade Sp1 may offer a potent, low-toxicity strategy to treat both oncogenesis and fibrogenesis.
Area of Science:
- Molecular Biology
- Oncology
- Fibrosis Research
Background:
- The Sp1 transcription factor is crucial for gene expression in both cancer (oncogenesis) and fibrotic diseases (fibrogenesis).
- Mithramycin inhibits Sp1 DNA binding but has clinical side effects; alternative drugs promote Sp1 protein degradation.
Purpose of the Study:
- To explore the potential of combining low-dose mithramycin with Sp1-degrading drugs for cancer treatment.
- To investigate if this combinatorial approach could also target fibrotic processes.
Main Methods:
- Review of existing research on Sp1 function in cancer and fibrosis.
- Analysis of studies combining mithramycin with Sp1-targeting drugs.
Main Results:
- Combinations of low-dose mithramycin and Sp1-degrading drugs show potent antitumorigenic effects with reduced toxicity.
- Sp1 also regulates profibrotic genes like collagen type I and CCN2.
Conclusions:
- A combinatorial therapeutic strategy targeting Sp1 may simultaneously combat cancer and fibrosis.
- This approach offers a promising avenue for treating complex diseases involving both oncogenesis and fibrogenesis.
More Related Videos
09:52A Mimic of the Tumor Microenvironment: A Simple Method for Generating Enriched Cell Populations and Investigating Intercellular Communication
Published on: September 20, 2016
09:01Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
Published on: July 3, 2025
Related Concept Videos
Cancer
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cirrhosis II: Pathophysiology
Abnormal Proliferation
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Healing I: Introduction